Novo-Med Zielinski I Wspolnicy Sp. j.
- Address
- lock Available on a paid plan
Novo-Med Zielinski i Wspolnicy Sp. j. - Neurological Disorders Research Center
Novo-Med Zielinski i Wspolnicy Sp. j. is a specialized clinical research center with extensive expertise in neurological and neurodegenerative disorders. The center demonstrates particular strength in conducting complex Phase 1-3 trials across a diverse spectrum of central nervous system conditions, from autoimmune neurological diseases to cognitive impairment and epilepsy disorders.
- Multiple Sclerosis research, including relapsing-remitting and primary progressive forms, with expertise in comparative efficacy and biosimilar studies
- Epilepsy clinical trials focusing on focal-onset seizures, primary generalized tonic-clonic seizures, and refractory epilepsy with novel antiseizure medications
- Neuromuscular disorders, particularly generalized Myasthenia Gravis, evaluating innovative complement inhibitors and immunomodulatory therapies
- Alzheimer's Disease and cognitive impairment research, including mild cognitive impairment and mild to moderate dementia studies
The center's portfolio reflects advanced capabilities in evaluating pharmacokinetic comparability studies, disease-modifying therapies, and novel therapeutic mechanisms. Their experience spans various study designs including randomized controlled trials, open-label extensions, and long-term safety evaluations. Additional research interests include Parkinson's Disease and menstrual migraine, demonstrating comprehensive expertise across the neurological therapeutic landscape with emphasis on both acute symptom management and long-term disease progression.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Xenon Pharmaceuticals Inc.2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Xenon Pharmaceuticals Inc.3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Novo-Med Zielinski I Wspolnicy Sp. j.
lock Showing 1 of 21 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis | Biogen Idec Research Limited | Phase II | Not Recruiting | Oct 2023 | Feb 2026 |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azetukalner | 3 | Unknown | 2023-08-11 | 2024-02-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.